Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.

Autor: Massaro F; PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.; Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy., Pavone V; Department of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase, Italy., Stefani PM; Hematology Unit, General Hospital Ca' Foncello, Treviso, Italy., Botto B; Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy., Pulsoni A; Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Patti C; Division of Onco-Hematology, Azienda Villa Sofia-Cervello, Palermo, Italy., Cantonetti M; Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata, Rome, Italy., Visentin A; Hematology and Clinical Immunology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy., Scalzulli PR; Department of Hematology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy., Rossi A; Hematology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy., Galimberti S; Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Italy., Cimminiello M; Hematology, San Carlo Hospital, Potenza, Italy., Gini G; Division of Hematology, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy., Musso M; Department of Oncology, Hematology and BMT Unit, Casa di Cura La Maddalena, Palermo, Italy., Sorio M; Department of Clinical and Experimental Medicine, Hematology and Bone Marrow Transplant Unit, University of Verona, Verona, Italy., Arcari A; Hematology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy., Zilioli VR; Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Luppi M; Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy., Mannina D; Unit of Haematology, Azienda Ospedaliera Papardo, Messina, Italy., Fabbri A; Hematology, Azienda Ospedaliero-Universitaria Senese, Siena, Italy., Pietrantuono G; Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, Italy., Annibali O; Unit of Haematology and Stem Cell Transplantation, Campus Bio-Medico University, Rome, Italy., Tafuri A; Department of Clinical and Molecular Medicine and Hematology, Sant'Andrea - University Hospital - Sapienza, University of Rome, Rome, Italy., Prete E; Department of Hematology and Bone Marrow Transplant, Hospital Card. G. Panico, Tricase, Italy., Mulè A; Division of Onco-Hematology, Azienda Villa Sofia-Cervello, Palermo, Italy., Barbolini E; Gruppo Amici dell'Ematologia GRADE-Onlus Foundation, Reggio Emilia, Italy., Marcheselli L; Fondazione Italiana Linfomi Onlus, Modena, Italy., Luminari S; Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy., Merli F; Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Jazyk: angličtina
Zdroj: Hematological oncology [Hematol Oncol] 2022 Feb; Vol. 40 (1), pp. 31-39. Date of Electronic Publication: 2021 Nov 01.
DOI: 10.1002/hon.2939
Abstrakt: The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post-ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression-free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post-ASCT BV maintenance in the real-life setting of 23 Italian hematology centers. This population included naïve patients and those previously exposed to BV. Median follow-up was 20 months. Patients presented a median of two lines of treatment pre-ASCT, with 51% receiving BV. Twenty-nine percent of patients had at least two high-risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET-CT, a Deauville score (DS) of 1-3 was reported in 75% and 78% of pre- and post-ASCT evaluations, respectively. Grade 3-4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three-year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3-year PFS and OS were 54% and 71%, respectively, for naïve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46; p = 0.003) and post-ASCT DS 4-5 (HR 3.14; p = 0.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post-ASCT BV maintenance is an effective, safe treatment option for cHL naïve patients and those previously exposed to BV.
(© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: